Data Presented For ENMD-2076 In Xenograft Models Of Human Hepatocellular Carcinoma

   Data Presented For ENMD-2076 In Xenograft Models Of Human Hepatocellular

PR Newswire

ROCKVILLE, Md., Oct. 22, 2013

ROCKVILLE, Md., Oct. 22, 2013 /PRNewswire/ --EntreMed, Inc. (NASDAQ: ENMD), 
a clinical-stage pharmaceutical company developing therapeutics for the
treatment of a variety of cancers, announced today  the presentation of
preclinical data for a study comparing the efficacy of ENMD-2076 against that
of standard of care agents including sorafenib, doxorubicin, and 5-FU for
human hepatocellular carcinoma (HCC) models. The results of the study were
presented at AACR-NCI-EORTC International Conference being held this week in
Boston, Massachusetts.

(Logo: )

The data presented demonstrate significant in vivo activity of ENMD-2076
against three different human hepatocellular carcinoma xenograft models and
concluded that ENMD-2076 showed robust antitumor activity against the cell
line-derived xenograft models of human HCC superior to that of sorafenib,
doxorubicin, and 5-FU.

Ken K. Ren, Ph.D., EntreMed's Chief Executive Officer, commented, "HCC
represents the third leading cause of cancer deaths worldwide. There are
unmet medical needs for drugs with better safety and efficacy. This  in vivo
preclinical study data is affirmative with our previous in vitro findings that
greater than 60% of 21 liver cancer-derived cell lines we screened are
significantly inhibited by ENMD-2076 treatment. It also indicates that
ENMD-2076 may be effective in patients resistant to sorafenib or 5-FU. In our
Phase 1 trial of ENMD-2076, partial response with prolonged progression free
survival was observed in a patient with liver cancer who relapsed from
standard care including liver transplantation and sorafenib treatment. This
preclinical study provides support for further clinical investigation of the
drug candidate in HCC patients who do not tolerate, or have failed or relapsed
from other systemic treatment, particularly sorafenib or 5-FU. We believe
that ENMD-2076 has potential in the HCC market, especially in China, where
more than 50% of global incidence occurs."

To view the poster presentation, visit the Company's website at

About ENMD-2076
ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a
unique kinase selectivity profile and multiple mechanisms of action.
ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine
kinase targets in addition to the Aurora A kinase. Aurora kinases are key
regulators of mitosis (cell division), and are often over-expressed in human
cancers. ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases which have
been shown to play important roles in the pathology of several cancers.
ENMD-2076 has shown promising activity in Phase 1 clinical trials in solid
tumor cancers, leukemia, multiple myeloma, and is currently completing a Phase
2 trial for ovarian cancer. EntreMed is currently conducting a Phase 2 study
of ENMD-2076 in triple-negative breast cancer, a Phase 2 study in
advanced/metastatic soft tissue sarcoma, and expecting to initiate a Phase 2
study in ovarian clear cell carcinoma. ENMD-2076 has received orphan drug
designation from the FDA for the treatment of ovarian cancer, multiple myeloma
and acute myeloid leukemia.

About EntreMed
EntreMed is a clinical-stage pharmaceutical company employing a drug
development strategy primarily in the United States and China to develop
targeted therapeutics for the global market. Its lead compound, ENMD-2076, a
selective angiogenic kinase inhibitor, has completed several Phase 1 studies
in solid tumors, multiple myeloma, and leukemia, and is currently completing a
multi-center Phase 2 study in ovarian cancer. EntreMed is currently
conducting a Phase 2 study of ENMD-2076 in triple-negative breast cancer, a
Phase 2 study of ENMD-2076 in advanced/metastatic soft tissue sarcoma, and is
expecting to initiate a Phase 2 study in ovarian clear cell carcinoma. The
Company is headquartered in Rockville, Maryland and has a wholly-owned
subsidiary in Beijing, China. Additional information about EntreMed is
available on the Company's web site at and in various filings
with the Securities and Exchange Commission (the SEC).

Forward Looking Statements
This release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act with respect to the outlook for
expectations for future financial or business performance, strategies,
expectations and goals. Forward-looking statements are subject to numerous
assumptions, risks and uncertainties, which change over time. Forward-looking
statements speak only as of the date they are made, and no duty to update
forward-looking statements is assumed.

Actual results could differ materially from those currently anticipated due to
a number of factors, including: the risk that we may be unable to continue as
a going concern as a result of our inability to raise sufficient capital for
our operational needs; the possibility that we may be delisted from trading on
the Nasdaq Capital Market; the volatility of our common stock; the difficulty
of executing our business strategy in China; our inability to enter into
strategic partnerships for the development, commercialization, manufacturing
and distribution of our proposed product candidate or future candidates; risks
relating to the need for additional capital and the uncertainty of securing
additional funding on favorable terms; declines in actual sales of Thalomid^®
resulting in reduced or no royalty payments; risks associated with our product
candidates; any early-stage products under development; results in preclinical
models are not necessarily indicative of clinical results; uncertainties
relating to preclinical and clinical trials, including delays to the
commencement of such trials; the lack of success in the clinical development
of any of our products; dependence on third parties; and risks relating to the
commercialization, if any, of our proposed products (such as marketing,
safety, regulatory, patent, product liability, supply, competition and other
risks). Such factors, among others, could have a material adverse effect upon
our business, results of operations and financial condition. We caution
readers not to place undue reliance on any forward-looking statements, which
only speak as of the date made. Additional information about the factors and
risks that could affect our business, financial condition and results of
operations, are contained in our filings with the U.S. Securities and Exchange
Commission ("SEC"), which are available at

Investor Relations
EntreMed, Inc.

SOURCE EntreMed, Inc.

Press spacebar to pause and continue. Press esc to stop.